Quantification of ER/PR expression in ovarian low-grade serous carcinoma

Gynecologic Oncology

Volumn 128, Issue 2, 2013, Pages 371-376

  Escobar, Jorge ^a   Klimowicz, Alexander C ^a   Dean, Michelle ^a   Chu, Pamela ^b   Nation, Jill G ^b   Nelson, Gregg S ^b   Ghatage, Prafull ^b   Kalloger, Steve E ^c   Köbel, Martin ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AQUA; ER; Low grade serous carcinoma; Ovarian cancer; PR; Quantification

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CARCINOMA; COHORT ANALYSIS; HIGH GRADE SEROUS CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; LOW GRADE SEROUS CARCINOMA; MAJOR CLINICAL STUDY; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROUS BORDERLINE TUMOR; TISSUE MICROARRAY; UTERINE TUBE;

ADULT; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84872845081     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.10.013     Document Type: Article

References (36)

1. K.M. Schmeler, C.C. Sun, D.C. Bodurka, M.T. Deavers, A. Malpica, and R.L. Coleman Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 108 2008 510 514
2. K.M. Schmeler, C.C. Sun, A. Malpica, M.T. Deavers, D.C. Bodurka, and D.M. Gershenson Low-grade serous primary peritoneal carcinoma Gynecol Oncol 121 2011 482 486
3. G. Singer, R.J. Kurman, H.W. Chang, S.K. Cho, and IeM. Shih Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 2002 1223 1228 (Pubitemid 34411626)
4. K.K. Wong, Y.T. Tsang, M.T. Deavers, S.C. Mok, Z. Zu, and C. Sun BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas Am J Pathol 177 2010 1611 1617
5. A.A. Ahmed, D. Etemadmoghadam, J. Temple, A.G. Lynch, M. Riad, and R. Sharma Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 2010 49 56
6. M. Köbel, A. Reuss, A.D. Bois, S. Kommoss, F. Kommoss, and D. Gao The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas J Pathol 222 2010 191 198
7. I. Diaz-Padilla, A.L. Malpica, L. Minig, L.M. Chiva, D.M. Gershenson, and A. Gonzalez-Martin Ovarian low-grade serous carcinoma: a comprehensive update Gynecol Oncol 126 2012 279 285
8. K.K. Wong, K.H. Lu, A. Malpica, D.C. Bodurka, H.S. Shvartsman, and R.E. Schmandt Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis Int J Gynecol Pathol 26 2007 404 409 (Pubitemid 47476325)
9. A. Garrett, and M.A. Quinn Hormonal therapies and gynaecological cancers Best Pract Res Clin Obstet Gynaecol 22 2008 407 421 (Pubitemid 351292329)
10. M. Köbel, S.E. Kalloger, N. Boyd, S. McKinney, E. Mehl, and C. Palmer Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 2008 e232
11. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451 1467
12. K.L. Molpus, H. Wu, and A.F. Fuller Recurrent psammocarcinoma of the peritoneum with complete response to tamoxifen therapy Gynecol Oncol 68 1998 206 209 (Pubitemid 28150776)
13. D.M. Gershenson, C.C. Sun, R.B. Iyer, A.L. Malpica, J.J. Kavanagh, and D.C. Bodurka Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 125 2012 661 666
14. A.B. Bromley, A.D. Altman, P. Chu, J.G. Nation, G.S. Nelson, and P. Ghatage Architectural patterns of ovarian/pelvic high-grade serous carcinoma Int J Gynecol Pathol 31 2012 397 404
15. A. Malpica, M.T. Deavers, C. Tornos, R.J. Kurman, R. Soslow, and J.D. Seidman Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma Am J Surg Pathol 31 2007 1168 1174 (Pubitemid 47207118)
16. D.C. Allred, J.M. Harvey, M. Berardo, and G.M. Clark Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 1998 155 168 (Pubitemid 28144151)
17. R.L. Camp, G.G. Chung, and D.L. Rimm Automated subcellular localization and quantification of protein expression in tissue microarrays Nat Med 8 2002 1323 1327 (Pubitemid 35373567)
18. S. Otsuka, A.C. Klimowicz, K. Kopciuk, S.K. Petrillo, M. Konno, and D. Hao CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer J Thorac Oncol 6 2011 1169 1178
19. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, and D.M. Gershenson Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504 (Pubitemid 38436523)
20. I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert, P. Dimitrov, L.M. Sapinoso, and M. Orlowska-Volk Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential Oncogene 24 2005 1053 1065 (Pubitemid 40313882)
21. T. Bonome, J.Y. Lee, D.C. Park, M. Radonovich, C. Pise-Masison, and J. Brady Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 2005 10602 10612 (Pubitemid 41743756)
22. M.A. Crispens, D. Bodurka, M. Deavers, K. Lu, E.G. Silva, and D.M. Gershenson Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential Obstet Gynecol 99 2002 3 10 (Pubitemid 34075460)
23. T.A. Longacre, J.K. McKenney, H.D. Tazelaar, R.L. Kempson, and M.R. Hendrickson Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or = 5-year) follow-up Am J Surg Pathol 29 2005 707 723 (Pubitemid 40734421)
24. R.T. Burks, M.E. Sherman, and R.J. Kurman Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors Am J Surg Pathol 20 1996 1319 1330 (Pubitemid 26367203)
25. G.M. Abu-Jawdeh, T.W. Jacobs, J. Niloff, and S.A. Cannistra Estrogen receptor expression is a common feature of ovarian borderline tumors Gynecol Oncol 60 1996 301 307 (Pubitemid 26058778)
26. T. May, C. Virtanen, M. Sharma, A. Milea, H. Begley, and B. Rosen Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary Gynecol Oncol 117 2010 9 17
27. W. Remmele, and H.E. Stegner Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe 8 1987 138 140
28. S.E. Kalloger, M. Köbel, S. Leung, E. Mehl, D. Gao, and K.M. Marcon Calculator for ovarian carcinoma subtype prediction Mod Pathol 24 2011 512 521
29. J. Terry, E.E. Torlakovic, J. Garratt, D. Miller, M. Köbel, and J. Cooper Implementation of a Canadian External Quality Assurance Program for breast cancer biomarkers: an initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry Appl Immunohistochem Mol Morphol 17 2009 375 382
30. A.W. Welsh, C.B. Moeder, S. Kumar, P. Gershkovich, E.T. Alarid, and M. Harigopal Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells J Clin Oncol 29 2011 2978 2984
31. C.B. Moeder, J.M. Giltnane, S.P. Moulis, and D.L. Rimm Quantitative, fluorescence-based in-situ assessment of protein expression Methods Mol Biol 520 2009 163 175
32. S. Loi, B. Haibe-Kains, C. Desmedt, P. Wirapati, F. Lallemand, and A.M. Tutt Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen BMC Genomics 9 2008 239
33. S. Liu, S.K. Chia, E. Mehl, S. Leung, A. Rajput, and M.C. Cheang Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients Breast Cancer Res Treat 119 2010 53 61
34. M. Stendahl, L. Rydén, B. Nordenskjöld, P.E. Jönsson, G. Landberg, and K. Jirström High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients Clin Cancer Res 12 2006 4614 4618 (Pubitemid 44297812)
35. M. Köbel, D. Turbin, S.E. Kalloger, D. Gao, D.G. Huntsman, and C.B. Gilks Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites Int J Gynecol Pathol 30 2011 366 371
36. M. Köbel, S.E. Kalloger, J.L. Santos, D.G. Huntsman, C.B. Gilks, and K.D. Swenerton Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications Gynecol Oncol 116 2010 50 56